Blaze Bioscience Inc.   Report issue

For profit Phase 3
Founded: Seattle WA United States (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2013
NCT02097875
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Blaze Bioscience Australia Pty Ltd | Blaze Bioscience Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

tozuleristide (9 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Central Nervous System Neoplasms (Phase 3)

Glioma (Phase 1)

Nervous System Neoplasms (Phase 3)

Sarcoma (Phase 1)

Skin Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 1